Theracos (United States)

EGT1442, a potent and selective SGLT2 inhibitor, attenuates blood glucose and HbA1c levels in db/db mice and prolongs the survival of stroke-prone rats

Wenbin Zhang, Ajith Welihinda, Jordan Mechanic et al. · Pharmacological Research · 2011 · 76 citations

Selective Sglt2 Inhibitor, Medicine, Diabetes +13

Design, Synthesis, and Biological Evaluation of Deuterated <i>C</i>-Aryl Glycoside as a Potent and Long-Acting Renal Sodium-Dependent Glucose Cotransporter 2 Inhibitor for the Treatment of Type 2 Diabetes

Ge Xu, Binhua Lv, Jacques Y. Roberge et al. · Journal of Medicinal Chemistry · 2014 · 63 citations · Full text

Urinary Glucose Excretion, Oxidative Stress, Molecular Pharmacology +16

A 96‐week, multinational, randomized, double‐blind, parallel‐group, clinical trial evaluating the safety and effectiveness of bexagliflozin as a monotherapy for adults with type 2 diabetes

Yuan‐Di C. Halvorsen, Geoffrey Walford, Joseph M. Massaro et al. · Diabetes Obesity and Metabolism · 2019 · 39 citations

Exploration of O-spiroketal C-arylglucosides as novel and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors

Binhua Lv, Baihua Xu, Feng Yan et al. · Bioorganic & Medicinal Chemistry Letters · 2009 · 37 citations · Full text

Medicinal Chemistry, Biochemistry, Medicine +9

C-Aryl glucosides substituted at the 4′-position as potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes

Baihua Xu, Feng Yan, Huawei Cheng et al. · Bioorganic & Medicinal Chemistry Letters · 2011 · 33 citations · Full text

Molecular Pharmacology, Diabetes Management, Biochemistry +9